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Abstract A number of signaling pathways might be
frequently disrupted in acute myeloid leukemia (AML).
We questioned whether the dual SRC/ABL kinase inhibitor
dasatinib can affect AML cells and whether differences can
be observed with normal CD34
+ cells. First, we demon-
strated that normal cord blood (CB) CD34
+ cells were
unaffected by dasatinib at a low concentration (0.5 nM) in
the long-term culture on MS5 stromal cells. No changes
were observed in proliferation, differentiation, and colony
formation. In a subset of AML cases (3/15), a distinct
reduction in cell proliferation was observed, ranging from
48% to 91% inhibition at 0.5 nM of dasatinib, in particular,
those characterized by BCR–ABL or KIT mutations.
Moreover, the inhibitory effects of dasatinib were cytokine
specific. Stem cell factor-mediated proliferation was signifi-
cantlyimpaired, associated with a reduced phosphorylation of
ERK1/2 and STAT5, whereas no effect was observed on
interleukin-3 and thrombopoietin-mediated signaling despite
SRC activation. In conclusion, this study demonstrates that
dasatinib is a potential inhibitor in a subgroup of AML,
especially those that express BCR–ABL or KIT mutations.
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Introduction
Acute myeloid leukemia (AML) is a clonal hematopoietic
disorder with an early block in the differentiation program.
The malignant disorder is organized in hierarchy whereby a
limited number of cells, which are considered leukemic
initiating cells (LICs), have the property to maintain the
leukemic phenotype and are enriched in the CD34
+ cell
fraction [1, 2]. The malignant transformation in AML has
been proposed as the consequence of collaboration between
several mutations, including both mutations in transcription
factors resulting in impaired differentiation and constitu-
tively activated receptor tyrosine kinases (RTKs), such as
FLT3 and KIT, conferring proliferative and survival
advantages to hematopoietic cells [3].
Dasatinib has been designed as a dual ABL/SRC family
kinase (SFK) inhibitor [4]. It is effective in imatinib-
resistant chronic myeloid leukemia (CML) by binding both
the active and inactive form of BCR–ABL, as well as the
SFKs, and subsequently affects also the important down-
stream targets including STAT5 and ERK1/2 [5–7].
Dasatinib is also known as kinase inhibitor of KIT and
platelet-derived growth factor receptor, as well as ephrin A
receptor kinases [4, 8]. Nonreceptor protein tyrosine
kinases (TKs) including SFKs interact with and participate
in signaling from RTKs [9]. It has been demonstrated that
Lyn, a member of SFKs, is an important component of the
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component linking FLT3/ITD to STAT5 [10]. These SFKs
are frequently constitutively expressed in AML, especially
Lyn, Hck, and Fgr [11]. KIT expression was detected in
approximately 70% of de novo AMLs and 95% of relapsed
AMLs [12]. The increased KIT intensity was correlated
with decreased overall survival in AML patients [13]. And
KIT mutations have been preferentially associated with
core-binding factor (CBF) AML with either an inv(16) or a
t(8;21) karyotype [14]. In vitro study has shown that
dasatinib at low dose can inhibit the proliferation of AML
Kasumi-1 cell line, which has a gain-of-function KIT
mutation [15]. A recent case report showed that combined
treatment with chemotherapy and dasatinib could achieve
long-term hematologic and molecular remission in a patient
with systemic mastocytosis and AML with mutant KIT-
D816V expression [16]. So far, it is unresolved whether
patients' AML cells are affected by dasatinib because, in
AML cells, a number of collaborative signaling pathways
might be disrupted. Here we performed long-term cultures
with AML CD34
+ cells, as well as normal cord blood (CB)
CD34
+ cells on MS5 murine stromal cells in the absence or
presence of dasatinib, to study the long-term expansion,
self-renewal, and hematopoietic differentiation.
Materials and methods
Reagents and antibodies
Dasatinib (BMS-354825) was provided by Bristol-Myers
Squibb Company (Princeton, NJ, USA) and prepared as a
10 mM stock solution in dimethylsulfoxide (DMSO),
stored in aliquots at −20°C, and diluted in DMSO before
treatment on the cells. Purified mouse anti-human STAT5
(pY694), CD11b-PE, CD14-FITC, and CD15-APC were
purchased from BD Biosciences (Breda, the Netherlands).
Phospho-SRC family (Tyr416) antibody, phospho-ERK1/2
(Thr202/Tyr204) antibody, and phospho-p70 S6 kinase
(Thr389) antibody were purchased from Cell Signaling
(Leiden, the Netherlands). ERK1 antibody was obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Isolation of normal and leukemic CD34
+ cells
Normal CD34
+ cells were derived from neonatal CB from
healthy full-term pregnancies from the obstetrics depart-
ments of the Martini Hospital and University Medical
Center in Groningen, the Netherlands, after informed
consent. After Ficoll separation of mononuclear cells,
CD34
+ cells were enriched by magnetically activated
cell-sorting CD34 progenitor kit (Miltenyi Biotec, Utrecht,
the Netherlands). Acute myeloid leukemia blasts from
peripheral blood cells or bone marrow cells from untreated
patients with AML were studied after informed consent.
Acute myeloid leukemia mononuclear cells were isolated
by density gradient centrifugation, and CD34
+ cells were
selected by MoFLo sorting (DakoCytomation, Carpinteria,
CA, USA).
Liquid culture conditions of cell lines and primary cells
K 5 6 2c e l ll i n ew a sc u l t u r e di nR P M I1 6 4 0m e d i u m
(Biowhittaker, Verviers, Belgium) supplemented with L-
glutamate, 10% fetal calf serum (FCS; Sigma, Zwijndrecht,
the Netherlands), and 1% penicillin/streptomycin (P/S).
Mo7e cell line was routinely propagated in RPMI 1640
with 5% FCS, 1% P/S, and 10 ng/ml interleukin-3 (IL-3;
Gist-Brocades, Delft, the Netherlands). Before preparing
cell lysates, Mo7e cells were deprived of cytokine
overnight in RPMI with 0.5% FCS and subsequently
stimulated with 20 ng/ml stem cell factor (SCF; Immunex
Corporation, Seattle, WA), IL-3, or thrombopoietin (TPO;
Kirin, Tokyo, Japan) for 15 min, separately. Dasatinib was
added 2 h before cytokine stimulation. SKNO-1 cell line
(kindly provided by Prof. Dr. M. Lübbert) was routinely
propagated in RPMI 1640 with 10% FCS, 1% P/S, and with
10 ng/ml granulocyte macrophage colony-stimulating factor
(GM-CSF; Genetics Institute, Cambridge). Thirty thousand
CB CD34
+ cells were cultured in Iscove's modified
Dulbecco's (IMD) medium (PAA Laboratories, Pasching,
Austria) supplemented with 10% FCS, 1% glutamine, and
1% P/S, supplemented with the following cytokines: SCF
(20 ng/ml), IL-3 (20 ng/ml), or in combination (SCF with
IL-3 at 20 ng/ml), or TPO (20 ng/ml) combined with IL-3
(5 ng/ml). Cultures were demi-depopulated at days 7 and 14
for analysis.
Long-term cultures on MS5 stromal cells
The 40,000 AML CD34
+ cells were plated in 12-well plates
precoated with MS5 stromal cells. Cells were expanded in
LTC medium (α-MEM supplemented with heat-inactivated
12.5% FCS, heat-inactivated 12.5% horse serum, P/S,
2 mM glutamine, 57.2 μM β-mercaptoethanol and 1 μM
hydrocortisone) (all from Sigma) supplemented with
20 ng/ml IL-3, granulocyte colony-stimulating factor (G-
CSF; Rhone-Poulenc Rorer, Amstelveen, The Netherlands),
and TPO as described previously [17, 18]. Cultures were
kept at 37°C and 5% CO2 and demi-depopulated weekly for
analysis. In cocultures that generated leukemic cobblestone
areas (L-CAs), leukemic cells could be harvested from
these cocultures after 3 to 5 weeks to initiate secondary
cocultures on new MS5 stroma, a feature of self-renewing
cells that we do not observe with normal CB. Thirty
thousand CB CD34
+ cells were plated in T-25 flasks
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LTC medium and demi-depopulated weekly for analysis.
One hundred thousand SKNO-1 cells were plated in MS5
stromal cells precoated 12-well plates, expanding in RPMI
with 10% FCS and 1% P/S, with or without 10 ng/ml GM-
CSF. Demi-depopulation was performed.
KIT and FLT3 mutation analysis
Detection of the KIT-D816V mutation was performed with
real-time polymerase chain reaction (PCR) using primers
5′-TTGTGATTTTGGTCTAGCCAGACT-3′ and 5′-
GTGCCATCCACTTCACAGGTAG-3′ according to the
previous study [19]. Mutational analysis of ITD within the
JM domain of the FLT3 gene was performed with reverse
transcriptase PCR using primers 5′-CAATTTAGGTAT
GAAAGCC-3′ and 5′-CAAACTCTAAATTTTCTCT-3′,a s
previously described [20].
Colony-forming cell assay
Colony-forming cell (CFC) assay was performed as
previously described [21]. Briefly, CFC assays were
performed in 1.2% methylcellulose containing 30% FCS,
57.2 μM β-mercaptoethanol, and 2 mM glutamine (Stem-
Cell Technologies, Meylan, France), supplemented with
20 ng/ml IL-3, IL-6, G-CSF, SCF, and 1 U/ml erythropoi-
etin (Epo, Cilag; Eprex, Brussels, Belgium). One thousand
fresh CB CD34
+ cells or 10
4 expanded cells from MS5
coculture were plated in 1-ml CFC mixes per 35-mm dish
in duplicate. The colonies were scored 2 weeks later.
Fluorescence-activated cell sorter analysis
Cells were incubated with antibodies at 4°C for 30 min
before the analysis on a FACSCalibur (Becton Dickinson).
Data were analyzed using WinList 6.0 (Topsham, ME,
USA).
Cell lysis and Western blotting
Whole cell lysates were prepared in boiling sample buffer
(containing 2% sodium dodecyl sulfate [SDS], 10%
glycerol, 2% β-mercaptoethanol, 60 mM Tris–HCl, pH
6.8, and bromophenol blue). Protein aliquots were equally
resolved by 10% SDS polyacrylamide gel electrophoresis
and transferred to nitrocellulose membranes (Millipore,
Etten Leur, the Netherlands) using a semidry electroblotter
from Biorad (Veenendaal, the Netherlands). The mem-
branes were blocked in phosphate-buffered saline Tween 20
containing 5% nonfat milk before incubation with primary
antibodies. Detection was performed with horseradish
peroxidase-conjugated secondary antibody (DakoCytoma-
tion, Glostrup, Denmark) and enhanced chemiluminescence
(ECL) reagent (Roche Diagnostics, Basel, Switzerland).
Analysis of cell proliferation
K562 and Mo7e cells were suspended to a final concentra-
tion of 1×10
5 cells/ml in fresh growth mediums, plated in
12-well plate, and incubated with designated concentrations
of dasatinib for 72 h. Growth of Mo7e cells was driven by
20 ng/ml SCF, IL-3, or TPO. Cells were counted with
Coulter electronics (Mijdrecht, the Netherlands) after 24,
48, and 72 h.
Analysis of cell cycle status
K562 cells were harvested after treatment with dasatinib for
24 h and stained with hypotonic DNA buffer containing
sodium citrate (1 g/l; Merck, Schiphol-Rijk, the Nether-
lands), ribonuclease A (100 mg/ml), propidium iodide (PI;
1 mg/ml), and Triton X-100 (1:10 diluted) (Sigma).
Samples were analyzed on a FACSCalibur, and data were
analyzed with ModFit LT 3.1 (Topsham).
Analysis of apoptosis
K562 cells were incubated with dasatinib for 48 h, and
apoptosis was analyzed using an Annexin V staining kit (IQ
Products, Groningen, the Netherlands) according to the
manufacturer's recommendations. Briefly, cells were har-
vested, resuspended in 100-μl calcium buffer containing
5-μl annexin V, and incubated for 20 min at 4°C in the dark.
Cells were washed with calcium buffer and subsequently
incubated in 300-μl calcium buffer containing 2.5 μlo f
PI for 10 min. Analysis was performed on a FACSCalibur
with WinList 6.0 Analysis software.
Statistical analysis
The significance levels were determined by Student t test
between experimental groups. Data were reported as
mean ± standard error (SE) of the mean. A two-sided p
value <0.05 was considered statistically significant.
Results
Dasatinib impairs proliferation and colony formation,
but not differentiation of normal CB CD34
+ cells
The efficacy of dasatinib at low nanomolar concentrations
has been demonstrated in the BCR–ABL-positive K562 cell
line, as well as in primary CML CD34
+ cells [22–25]. We
first verified the effects of dasatinib in K562 cells, for
Ann Hematol (2010) 89:861–871 863defining the optimal dose–response. As depicted in Suppl
Fig. a, dasatinib at a concentration of 0.5 nM was already
effective in blocking the proliferation of K562 cells, with an
optimal inhibitory effect between 2 and 10 nM. These
inhibitory effects on cell proliferation were associated with
a reduced phosphorylation of SRC, ERK1/2, and STAT5
(Suppl Fig. b). Inhibition of these pathways resulted in a
cell cycle arrest with an enhanced percentage of cells in the
G0/G1 phase with a concomitant decline in cells in S phase
(p<0.05) (Suppl Fig. c). Moreover, the changes were
associated with an increased number of cells in apoptosis
(p<0.05) (Suppl Fig. d).
In contrast to BCR–ABL, which is specifically
expressed in CML, in a subset of acute lymphoblastic
leukemia and rarely in AML, the expression of SRC is
ubiquitous throughout the normal hematopoietic system,
and its activation has been associated with multiple
signaling pathways [26, 27]. In order to study the effects
of dasatinib treatment on normal stem/progenitor cells, CB
CD34
+ cells were expanded on MS5 stromal cells in the
absence or presence of dasatinib. Cultures were demi-
depopulated weekly for cell counting, CFC assays, and
fluorescence-activated cell sorter (FACS) analysis on
suspension cells. Dasatinib treatment resulted in a dose-
dependent growth disadvantage of normal CD34
+ progen-
itor cells (Fig. 1a). The growth was only significantly
reduced at a higher concentration (5 nM) of dasatinib, with
77.8±13.1% of control (p=0.04) at week 2, 61.0±16.5% of
control (p=0.02) at week 3, and 54.0±6.3% of control (p=
0.006) at week 4 (Fig. 1b). The treatment with dasatinib
(5 nM) resulted in a reduction in total progenitor (CFC)
output after 3 weeks of culture (62.2±10.3% of control, p=
0.01) (Fig. 1c). However, the colonies generated per 10
5
suspension cells were not affected by dasatinib treatment
(Fig. 1d). To study whether similar results could be
obtained in short-term CFC assays, we cultured 10
4
CD34
+ cells in methylcellulose culture assay with and
without dasatinib. The results demonstrated no significant
suppressive effect of dasatinib on colony formation
(Fig. 1e). Finally, FACS analysis of the suspension cells
at weeks 2 and 4 showed no changes in the myeloid
differentiation markers CD11b, CD14, and CD15, demon-
strating the reduced proliferation was not associated with an
impaired differentiation (Fig. 1f).
Dasatinib impairs expansion of AML CD34
+ cells
in long-term culture only in a subset of cases
It has been shown previously that the propagation of AML
cells partially depends on constitutively activation of
receptor kinases including FLT3 and KIT, and the autocrine
and paracrine production of growth factors that make
use of nonreceptor protein TKs [28]. Therefore, AML cells
(n=19) were studied in long-term stromal culture assays by
using exclusively the sorted CD34
+ cell fraction that is
enriched for leukemic stem cells, as has been described [17,
18]. The clinical characteristics of the studied patients,
including FAB classification, cytogenetics, and defined
mutations, are summarized in Table 1. In 79% (15/19) of
the tested AML cases, long-term expanding cocultures
could be generated (Fig. 2a, b). Variability in responsive-
ness of the different AMLs for dasatinib was observed. In
20% of the cases (3/15), a distinct decrease in long-term
cell expansion of AML CD34
+ cells was already observed
at a dose of 0.5 nM dasatinib, ranging from 48% to 91%
inhibition as compared to the untreated group. This
concentration of dasatinib showed less than 15% growth
inhibition in normal CD34
+ cells on stroma (Fig. 1a, b).
The growth curves of the three AML cases are shown in
Fig. 2c–e. To demonstrate whether dasatinib also inhibited
the self-renewal potential of the AML CD34
+ cells, we
performed replating experiments by harvesting the cells
from L-CAs after 3 to 5 weeks of coculture. These cells
were subsequently studied for their capacity to initiate
second (and third) cocultures on new MS5 stroma (Fig. 2c).
The results demonstrated that AML leukemic cells still
expanded on new MS5 stroma, and that the inhibitory effect
of dasatinib was less pronounced after replating. The AML
cells that responded to dasatinib were characterized by
chromosomal translocations or mutations in BCR–ABL
(n=1), KIT (n=1), or undetermined (n=1) mutations. In six
FLT3–ITD-positive AMLs, no suppressive effects of
dasatinib on cell expansion were noticed. Moreover, it
appeared that the responsiveness to dasatinib was indepen-
dent of the level of SRC mRNA expression (data not
shown). A remarkable finding was the fact that in the
additional AMLs (11/15), a stimulatory effect on cell
proliferation was observed at low-dose (0.5 nM) dasatinib
when the AML CD34
+ cells were cultured in long-term
stromal assay (Fig. 2a). An increase of 474% (range, 17–
2417%) was observed in time. This effect of dasatinib was
noticed after a period of 2 to 3 weeks of culture. At a higher
concentration (5 nM), this stimulatory effect disappeared in
most of the cases (Fig. 2b). Taken together, dasatinib shows
pronounced inhibitory effects on proliferation in a subset of
AML CD34
+ progenitor cells, whereas in the additional
cases, a stimulatory effect might be shown at low dose.
Dasatinib selectively impairs SCF-induced and mutant
KIT-driven signal transduction and proliferation
In view of the observed suppressive effects of dasatinib in a
mutant KIT AML, we further defined the role of dasatinib
on KIT receptor signaling by using cell line models with
either wild type (wt) (Mo7e cell line) or mutant KIT
receptor (SKNO-1 cell line), as well as in primary CB
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+ cells. We cultured the human myeloid leukemia cell
line Mo7e with SCF, IL-3, and TPO, and effects on
proliferation and downstream signaling pathways were
studied. The results showed that Mo7e cells cultured with
SCF demonstrated a significant decline in cell proliferation
at 5 nM, after culturing for 72 h (44±9% inhibition, p<
0.05). No inhibitory effect of dasatinib was shown if the
Mo7e cells were cultured with IL-3 or TPO or combina-
tions (Fig. 3a). In addition, we studied the downstream
targets that were inhibited by dasatinib and compared the
results with K562 cell line. As depicted in Fig. 3b,
constitutive phosphorylation of SRC and STAT5, but not
a) b)
d) e) c)
f)
0
10
20
30
40
50
60
70
80
90
100
wk 0 wk 2 wk 4
%
 
C
D
1
1
b
DMSO
0.5 nM
5 nM
0
10
20
30
40
50
60
70
80
90
100
wk 0 wk 2 wk 4
%
 
C
D
1
4
DMSO
0.5 nM
5 nM
0
10
20
30
40
50
60
70
80
90
100
wk 0 wk 2 wk 4
%
 
C
D
1
5
DMSO
0.5 nM
5 nM
0
200
400
600
800
1000
1200
1400
1600
1800
wk 0 wk 2 wk 3 wk 4
C
u
m
u
l
a
t
i
v
e
 
c
e
l
l
 
n
u
m
b
e
r
 
(
x
1
0
0
0
)
DMSO
0.5 nM
5 nM
CFCs/10,000 cells Total CFCs
0
20
40
60
80
100
120
wk 2 wk 3
%
 
c
o
l
o
n
i
e
s
 
o
f
 
c
o
n
t
r
o
l
0.5 nM
5 nM
**
0
20
40
60
80
100
120
140
wk 2 wk 3
%
 
c
o
l
o
n
i
e
s
 
o
f
 
c
o
n
t
r
o
l
0.5 nM
5 nM
0
20
40
60
80
100
120
140
Total CFCs Total BFU-Es
%
 
c
o
l
o
n
i
e
s
 
o
f
 
c
o
n
t
r
o
l
0.1 nM
0.5 nM
5 nM
0
20
40
60
80
100
120
wk 2 wk 3 wk 4
%
 
g
r
o
w
t
h
 
o
f
 
c
o
n
t
r
o
l
0.5 nM
5 nM
**
**
**
Fig. 1 Dasatinib impairs proliferation, but not colony formation and
differentiation of human CB CD34
+ progenitor cells. Cord blood
CD34
+ cells (3×10
4) were plated in T25 flask precoated with MS5
stromal cells. Cells were expanded in LTC medium with dasatinib
added weekly as indicated. Cultures were demi-depopulated weekly
for counting and CFC assay. a Representative figure of weekly
cumulative cell counts is shown. b Percentages of cell growth as
compared to the control group (% growth of control) on stroma by
adding dasatinib are shown as mean value from three independent
coculture experiments. c The total number of CFCs generated per T25
flask was calculated by the number of CFCs/10
4 plated cells
multiplied by the cell counts weekly. Percentages of colonies as
compared to the control group (% colonies of control) after dasatinib
treatment are shown. Data were from three independent coculture
experiments. d Cells (10
4) in suspension were plated at weeks 2 and 3
for CFC assay. Percentages of colonies as compared to the control
group (% colonies of control) after dasatinib treatment are shown. e
One thousand freshly isolated CB CD34
+ cells were analyzed for CFC
assay. Percentages of colonies as compared to the control group (%
colonies of control) after dasatinib treatment are shown. Data were
from three independent experiments. f The myeloid differentiation of
cells in suspension from the coculture system was monitored by FACS
with antibodies against CD11b, CD14, and CD15 at weeks 2 and 4.
Representative figures out of three independent experiments are
shown. Columns, means of three independent experiments; bars, SE
(**p<0.05)
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significant reduction in p-ERK1/2, p-STAT5, and p-p70S6k
was shown in SCF-stimulated cells pretreated with dasatinib
for 2 h. Moreover, the inhibitory effects were observed at a
concentration more than 2 nM, whereas the inhibitory effects
on BCR–ABL-mediated signaling was already shown at a
concentration less than 0.5 nM (Suppl Fig. b). In contrast, no
effects were observed on the IL-3 and TPO-mediated
phosphorylation. A remarkable finding was that none of
the cytokines were strong stimulators for SRC phosphoryla-
tion on top of the constitutive levels. Moreover, this SRC
activity was not inhibited by dasatinib (Fig. 3b). Taken
together, the inhibitory effects on SCF-induced proliferation
and signal transduction pathways indicate dasatinib is a
stronger KIT kinase inhibitor, rather than an SRC inhibitor.
KIT is expressed in normal stem and progenitor cells,
regulating quiescence, self-renewal, and proliferation of
stem cells [29, 30]. Therefore, CB CD34
+ cells were
cultured with SCF, IL-3, and TPO to observe whether
dasatinib had inhibitory effects on SCF-induced prolifera-
tion in normal progenitor cells. Representative growth
curves are shown in Fig. 3c, and mean values of growth
inhibition are shown in Fig. 3d. The results showed that CB
CD34
+ cells cultured with SCF demonstrated a significant
decline in cell proliferation at 5 nM (7.8±0.2% of control,
p<0.001), which was also noticed if SCF was combined
with IL-3 (15.6±2.8% of control, p=0.02). No inhibitory
effect of dasatinib was shown if the CD34
+ cells were
cultured with IL-3, TPO, or combinations. However, IL-3
alleviated the SCF effect (Fig. 3d).
To further evaluate these findings in the malignant
counterpart, we used the GM-CSF dependent SKNO-1 cell
line, which was characterized by a homozygous N822K
KIT mutation [31, 32]. The SKNO-1 cells were studied
with and without dasatinib treatment in long-term MS5
stromal culture assay in the presence or absence of GM-
CSF. SKNO-1 cells showed 17-fold expansion compared to
the control cultures without GM-CSF (Fig. 3e). In the
presenceofGM-CSF,43±9%growthinhibitionwasachieved
at1nMofdasatinib(p>0.05), which was further enhanced at
10 nM (66±13% growth inhibition, p<0.05). The inhibitory
effects of dasatinib were more pronounced in the absence of
GM-CSF (data not shown). Subsequently replating experi-
ments were performed with SKNO-1 cells cultured with
Patient ID FAB % CD34
+ BM/PB Expansion Karyotype FLT3-ITD KIT mutation
1M 7 4 3 P B Y e s −7; +21 −−
2 M2 26 PB Yes BCR-ABL, inv (16) − ND
3 M2 42 BM Yes t(8;21) − +
4 M2 52 PB Yes N + ND
5M 0 2 2 P B Y e s N +−
6 M5 88 PB Yes N − ND
7 M1 70 BM Yes +3q;−7;−10 −−
8 M0 70 BM Yes 5q−;+6 − ND
9M 1 1 9 P B Y e s N +−
10 M1 19 PB Yes N ND ND
11 M1 35 BM Yes N + −
12 M5 14 PB Yes t(11;20) + −
13 M1 57 PB Yes N −−
14 M5 10 BM Yes ND − ND
15 M5 0.5 PB Yes N + ND
16 M1 63 PB No 3p+; −7; +8 −−
17 M1 29 PB No del (9) + −
18 M4 17 PB No inv (16) − +
19 M5 13 BM No N + ND
Table 1 Summary of patient’s
clinical parameters
AML cells derived from bone
marrow (BM) or peripheral
blood (PB); Percentage of
CD34
+ (% CD34
+) in the total
AML mononuclear cell fraction;
AML CD34
+ cells cultured in
long-term culture assay demon-
strated an expansion (y/n); FAB,
French-American-British classifica-
tions; FLT3-ITD (internal tandem
duplication) was present (+) or
absent (−) in the AML cells; ND,
not determined; N, normal
Fig. 2 Dasatinib impairs expansion of a subset of AML CD34
+ cells in
long-term cultures. Acute myeloid leukemia CD34
+ cells (4×10
4)w e r e
sorted and plated in 12-well plates precoated with MS5 stromal cells.
Cells were expanded in LTC medium supplemented with 20 ng/ml IL-3,
G-CSF, and TPO. Dasatinib was added as indicated concentrations.
Cultures were demi-depopulated weekly for analysis. The responses to
dasatinib at 0.5 nM (n=15) (a)a n d5n M( n=14) (b)o fa l lA M L s
capable of long-term proliferation on stroma are shown, as compared to
the growth of control group (% growth of control). The time points for
cell counts indicated were at week 4/5. Cell counts indicated suspension
and adherent hematopoietic cells that were separated by sorting CD45
+
(human) cells. c–e Growth curves of three AMLs with growth reduction
by dasatinib treatment are shown. Weekly cumulative cell counts
represented cells in suspension except at time point of replating, where
cell counts reflected suspension and adherent hematopoietic cells. The
leukemic cells both in suspension and adherent layer were harvested
from the coculture at weeks 4 and 7 to initiate the second and third
cocultures on new MS5 stroma (AML no. 1)

866 Ann Hematol (2010) 89:861–871Responses to dasatinib at 0.5 nM in AML long-term culture assay (n=15)
Responses to dasatinib at 5 nM in AML long-term culture assay (n=14)
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the cells expanded but demonstrated a reduced susceptibility
to dasatinib in the second coculture (33±2% growth
inhibition at 10 nM, p>0.05). The reduced susceptibility to
dasatinib was not associated with an altered expression of
GM-CSF receptor or KIT or altered phosphorylation of
STAT5 or Erk (data not shown). Analysis on downstream
signaling transduction pathways demonstrated that only
p70S6k phosphorylation was down-regulated by dasatinib
at 10 nM in the presence of GM-CSF (Fig. 3f). Those results
demonstrate dasatinib can have a strong inhibitory effect on
KIT mutant cells dependent on coactivators.
Discussion
In the present study, we studied the effects of dasatinib in
normal and AML leukemic CD34
+ cells to demonstrate
whether dasatinib might be beneficial for the treatment of
AML patients. First, we demonstrated that normal CD34
+
cells were unaffected by dasatinib at a low concentration
(0.5 nM), including proliferation, differentiation, and
colony formation. In the long-term culture system, 20% of
the studied AML samples showed a distinct decrease in cell
expansion that was already observed at low dose of
dasatinib (0.5 nM). However, dasatinib seems to affect
especially the more mature leukemic progenitor population
because the AML CD34
+ cells responsible for replating
were only partially affected by dasatinib. Comparable
results have been described in CML, demonstrating that
dasatinib could target especially the progenitor cell popu-
lation but failed in eliminating the quiescent primitive cell
fraction [33]. The AMLs that responded well to dasatinib
treatment included samples with BCR–ABL and KIT
mutations. BCR–ABL is rarely detected in AML. Muta-
tions in KIT are associated with the chromosomal translo-
cation t(8;21) and inv(16) and are prognostic unfavorable
parameters in this subgroup of AML [34, 35]. However,
limited in vitro studies have been performed in this
subgroup of patients. We have observed that AML cells
with the t(8;21) propagate poorly in vitro in long-term
culture assay, and therefore, we extended our study with
myeloid leukemic cell line models including both wt and
mutant KIT kinase.
We demonstrated with cell lines as well as with CB cells
that dasatinib inhibited the SCF-mediated without inhibi-
tion on the IL-3 and TPO-mediated signaling. This finding
suggests that dasatinib is a much stronger KIT kinase
inhibitor than an SRC inhibitor. For the leukemic counter-
part, we used the SKNO-1 cell line, which is GM-CSF
dependent expressing homozygous N822K KIT mutation.
Dasatinib showed significant growth reduction on long-
term coculture assay, particularly in the absence of GM-
CSF, suggesting that dasatinib can target KIT mutation
effectively. Similar to what we observed in AML CD34
+
cells, the inhibitory effects of dasatinib in the presence of
GM-CSF were less pronounced when the cells were
replated on new stroma, suggesting that also in this test,
the progenitor cells were affected predominantly.
Although FLT3–ITD has been associated with increased
SRC kinase activity [36], none of six AMLs with FLT3–
ITD demonstrated a suppressive effect on dasatinib treat-
ment. This variability in responsiveness might be linked to
our observation that SRC is poorly inhibited by dasatinib or
that the activation of additional collaborative signaling
pathways have a more dominant effect on the cell
proliferation because of underlying mutations. However,
the obtained results suggest that the in vitro assay might be
of value to define potential AMLs that benefit from
dasatinib treatment in vivo.
A remarkable finding was that at low-dose concentration
of dasatinib (0.5 nM), a stimulatory effect on AML CD34
+
cell proliferation was observed in a large group of AMLs.
The cause of this stimulatory effect remains unclear and
requires further studies. In knockout mice deficient for SRC
kinases, it has been shown that these hematopoietic
progenitors have an enhanced proliferative response to
cytokine stimulation because of the absence of SRC kinase
family members [37]. However, because at higher concen-
tration of dasatinib this stimulatory effect almost disap-
peared, it is more likely that dasatinib affects the balance
Fig. 3 Dasatinib selectively impairs SCF-induced and mutant KIT-
driven signal transduction and proliferation. a Mo7e cell line was
cultured in RPMI with 5% FCS, supplemented with 20 ng/ml SCF, IL-3,
or TPO, in the absence or presence of increasing concentrations of
dasatinib.Average expansion ofthree independentexperiments isshown.
b Mo7e cells were deprived of cytokine in RPMI with 0.5% FCS
overnight, followed by the pretreatment with dasatinib for 2 h. The cells
were harvested for lysates after being left unstimulated (lane U) or
stimulated with 20 ng/ml SCF, IL-3, or TPO for 15 min. Cells (3×10
5)
were loaded for Western blot, analyzing with antibodies as indicated. c
Freshly isolated CB CD34
+ cells (3×10
4) were cultured in IMDM with
10% FCS, supplemented with SCF (20 ng/ml), IL-3 (20 ng/ml), or in
combination (SCF+IL-3), as well as TPO (20 ng/ml) and IL-3 (5 ng/ml)
(TPO+IL-3). Demi-depopulation was performed at days 7 and 14 for
counting. A representative experiment out of two independent experi-
ments is shown. d Percentages of growth after dasatinib treatment as
compared to control group (% growth of control) are shown as mean
value from two independent experiments. e SKNO-1 cells (10
5)w e r e
plated in 12-well plates precoated with MS5 stromal cells. Cells were
grown in RPMI supplemented 10% FCS, in the presence or absence
of GM-CSF (10 ng/ml). Dasatinib was added as indicated concen-
trations. Cultures were demi-depopulated as indicated time points for
analysis. Weekly cumulative cell counts represented cells in
suspension. The leukemic cells in suspension were harvested from
the coculture at day 16 to initiate the second cocultures on new MS5
stroma. f SKNO-1 cells were cultured in RPMI supplemented 10%
FCS, in the presence of GM-CSF (10 ng/ml), with dasatinib
treatment for 4 h. Cell lysates were prepared and subjected to
Western blotting using antibodies as indicated

Ann Hematol (2010) 89:861–871 869between different collaborative signaling pathways that
have opposite effects on cell proliferation. Furthermore,
we could exclude the possibility that the adaptor protein
Lnk binding directly to Y568 in KIT is involved. Previous
studies have shown that Lnk-deficient mice HSCs are
hyperresponsive to growth factor stimulation in particular
to TPO [38, 39]. However, in the present study, no effect of
dasatinib on the TPO signaling was observed. So, the
stimulatory effect in AML can unlikely be ascribed to the
blocking effect of dasatinib on Lnk.
In summary, the present study demonstrates that dasati-
nib is an effective inhibitor of the KIT-mediated signaling
in hematopoietic CD34
+ stem and progenitor cells and that
a subgroup of AMLs is responsive to the inhibitory effects
of dasatinib in vitro, in particular, those that express BCR–
ABL and especially KIT mutations.
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